-
Rodman & Renshaw Starts Ascentage Pharma Group (AAPG) at Buy
-
Ascentage Pharma presents four-year data on leukemia drug olverembatinib
-
Ascentage Pharma reports phase III data for leukemia drug candidate
-
Ascentage Pharma reports updated trial data for blood cancer drug
-
Oppenheimer Starts Ascentage Pharma Group (AAPG) at Outperform
-
Truist Securities Starts Ascentage Pharma Group (AAPG) at Buy
-
BTIG Starts Ascentage Pharma Group (AAPG) at Buy
-
Piper Sandler Starts Ascentage Pharma Group (AAPG) at Overweight
-
Ascentage Pharma prices $192.3 million share placement at HKD68.60
-
Ascentage Pharma announces proposed share placement by CEO affiliate
-
Ascentage Pharma gets China approval for cancer drug lisaftoclax
-
Ascentage Pharma (AAPG) Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines
-
JPMorgan Starts Ascentage Pharma Group (AAPG) at Overweight
-
Ascentage Pharma (AAPG) Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
-
Ascentage Pharma (AAPG) IPO opens flat at $17.25

